Your browser is no longer supported. Please, upgrade your browser.
Settings
SRRK [NASD]
Scholar Rock Holding Corporation
Index- P/E- EPS (ttm)-3.17 Insider Own0.10% Shs Outstand36.58M Perf Week-5.01%
Market Cap922.24M Forward P/E- EPS next Y-4.04 Insider Trans-26.48% Shs Float33.10M Perf Month-22.40%
Income-108.50M PEG- EPS next Q-0.85 Inst Own99.96% Short Float9.49% Perf Quarter-19.61%
Sales15.80M P/S58.37 EPS this Y-51.90% Inst Trans0.03% Short Ratio16.37 Perf Half Y-24.39%
Book/sh5.92 P/B4.49 EPS next Y-25.50% ROA-34.90% Target Price- Perf Year93.24%
Cash/sh8.13 P/C3.27 EPS next 5Y- ROE-55.60% 52W Range13.31 - 70.00 Perf YTD-45.25%
Dividend- P/FCF- EPS past 5Y- ROI-30.40% 52W High-62.20% Beta0.26
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low98.80% ATR2.30
Employees119 Current Ratio4.30 Sales Q/Q17.90% Oper. Margin- RSI (14)32.82 Volatility4.68% 7.58%
OptionableYes Debt/Eq0.11 EPS Q/Q-29.30% Profit Margin- Rel Volume0.68 Prev Close26.57
ShortableYes LT Debt/Eq0.11 EarningsAug 10 BMO Payout- Avg Volume191.74K Price26.46
Recom1.60 SMA20-10.46% SMA50-24.23% SMA200-32.55% Volume128,657 Change-0.41%
Apr-26-21Resumed Credit Suisse Outperform $65
Jan-11-21Initiated Credit Suisse Outperform $65
Jan-06-21Initiated JP Morgan Overweight $59
Mar-12-20Initiated Robert W. Baird Outperform $35
Oct-05-21 12:18PM  
Oct-03-21 08:00AM  
Sep-30-21 11:45AM  
Sep-29-21 02:28PM  
Sep-28-21 04:01PM  
Sep-23-21 11:31AM  
Sep-22-21 04:01PM  
Aug-17-21 07:40PM  
Aug-16-21 04:05PM  
Aug-15-21 12:00PM  
Aug-13-21 10:07PM  
Aug-11-21 11:43PM  
Aug-10-21 07:15PM  
04:15PM  
06:52AM  
Aug-09-21 08:39PM  
Aug-07-21 02:00PM  
Aug-05-21 08:21PM  
04:01PM  
Aug-03-21 10:55PM  
07:30AM  
Jul-30-21 03:00PM  
Jun-18-21 08:00AM  
Jun-11-21 07:30AM  
Jun-07-21 07:30AM  
May-27-21 08:01AM  
May-24-21 04:05PM  
May-19-21 05:05PM  
May-13-21 12:11PM  
07:30AM  
May-12-21 07:33AM  
May-11-21 04:30PM  
Apr-29-21 12:34PM  
Apr-26-21 04:59PM  
Apr-24-21 09:45PM  
Apr-21-21 08:37PM  
05:22PM  
Apr-19-21 11:17PM  
Apr-16-21 10:23PM  
Apr-14-21 11:57PM  
Apr-13-21 06:56AM  
06:25AM  
Apr-11-21 04:00AM  
Apr-10-21 08:30AM  
Apr-06-21 12:17PM  
07:48AM  
07:00AM  
Mar-22-21 04:20PM  
Mar-18-21 04:05PM  
Mar-17-21 04:05PM  
Mar-15-21 08:00AM  
Mar-09-21 05:45PM  
04:05PM  
Mar-04-21 12:30PM  
Feb-04-21 04:30PM  
Jan-27-21 08:00AM  
Jan-11-21 07:30AM  
Jan-04-21 04:01PM  
Dec-03-20 06:21PM  
Nov-29-20 11:41AM  
Nov-13-20 08:38AM  
Nov-12-20 08:00AM  
Nov-09-20 02:47PM  
08:00AM  
Nov-04-20 07:24AM  
Nov-02-20 04:05PM  
Oct-28-20 10:33PM  
10:24AM  
Oct-27-20 04:17PM  
10:46AM  
07:00AM  
Oct-19-20 07:30AM  
Sep-30-20 07:30AM  
Sep-09-20 07:30AM  
Sep-04-20 03:58PM  
Sep-02-20 04:30PM  
Aug-27-20 07:30AM  
Aug-13-20 07:30AM  
Aug-07-20 08:35AM  
07:00AM  
Aug-05-20 04:05PM  
Aug-03-20 07:30AM  
Jul-16-20 07:30AM  
Jul-14-20 07:30AM  
Jun-16-20 04:05PM  
Jun-12-20 07:30AM  
Jun-10-20 02:39PM  
May-27-20 04:30PM  
May-21-20 04:30PM  
May-18-20 07:30AM  
May-07-20 09:00PM  
04:15PM  
May-05-20 04:05PM  
12:30PM  
Apr-09-20 08:26AM  
07:30AM  
Mar-26-20 07:30AM  
Mar-24-20 07:30AM  
Mar-23-20 11:30AM  
Mar-12-20 07:25PM  
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FLIER JEFFREY S.DirectorOct 01Sale30.896,000185,32922,272Oct 05 08:15 AM
FLIER JEFFREY S.DirectorSep 20Sale34.0950017,0459,013Sep 21 04:46 PM
FLIER JEFFREY S.DirectorJul 26Sale31.666,000189,95428,272Jul 28 04:17 PM
Gilman MichaelDirectorMar 15Sale65.594,696307,99837,459Mar 17 05:03 PM
Gilman MichaelDirectorFeb 08Sale65.061,804117,36142,155Feb 11 07:14 AM
Carven Gregory JohnHead of ResearchJan 27Option Exercise15.116,619100,01382,734Jan 28 05:47 PM
Carven Gregory JohnHead of ResearchJan 27Sale56.5719,1001,080,40226,860Jan 28 05:47 PM
Carven Gregory JohnHead of ResearchJan 26Option Exercise8.8630,900273,82276,115Jan 28 05:47 PM
Gilman MichaelDirectorJan 26Option Exercise5.773,50120,20147,460Jan 28 05:48 PM
Gilman MichaelDirectorJan 26Sale59.263,501207,46943,959Jan 28 05:48 PM
Carven Gregory JohnHead of ResearchJan 26Sale59.4136,7742,184,82045,960Jan 28 05:47 PM